• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Academic-industry collaboration seeks new drugs, treatments for autism

Academic-industry collaboration seeks new drugs, treatments for autism

March 19, 2012
CenterWatch Staff

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

The collaboration, European Autism Interventions—a Multicenter Study for Developing New Medications (EU-AIMS), will be the largest single grant for autism research in the world and the largest for the study of any mental health disorder in Europe. The project will be ongoing for the next five years and brings together top scientists from universities around the world, experts from Autism Speaks—an autism science and advocacy organization—as well as major global drug companies from the European Federation of Pharmaceutical Industry Associations (EFPIA) including Roche, Eli Lilly, Servier, Janssen Pharmaceutica, Pfizer and Vifor Pharma.

EU-AIMS will focus on three areas: the development and validation of translational research approaches for the advancement of novel therapies for ASD; the identification, alignment and development of expert clinical sites across Europe to run clinical trials; and the creation of an interactive platform for ASD professionals and patients.

By the end of the project, EU-AIMS expects to provide novel validated cellular assays, animal models, new fMRI methods with dedicated analysis techniques and new PET radioligands, as well as new genetic and proteomic biomarkers for patient-segmentation or individual response prediction. It aims to establish a research network that can then move on to testing the investigational treatments in humans.

"The lack of effective pharmacological treatments for ASD has a profound effect on patients' lives.  We are excited that with this unique collaboration we may see a real shift in future treatment for this devastating disorder,” said Robert Ring, vice president of translational research, Autism Speaks

Will Spooren, project coordinator of EU-AIMS, added, “Recent genomic and functional studies have shed light on the pathophysiology of autism.  We need to work together if we want to fully harness those developments and pave the way for new treatment options which would cluster ASD patients sharing common pathophysiological features."

The research of EU-AIMS will receive support from the Innovative Medicines Initiative (IMI) Joint Undertaking, resources composed of financial contribution from the European Union's Seventh Framework Program, Autism Speaks and the EFPIA companies' in-kind contribution, resulting in a total of $38.7 million.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing